Mesenchymal stem/stromal cell (MSC)-based therapy holds promise for reversal of bone loss in osteoporosis. This phase 1 study establishes the safety and feasibility of intravenous administration of glycocalyx-engineered human MSCs and provides evidence that MSCs derived from the bone marrow of older individuals with osteoporosis retain clinically meaningful osteoregenerative capacity.